Tirzepatide Improves CVD Risk Biomarkers in Patients With diabetes: Study
Tirzepatide use is associated with a reduction in several biomarkers associated with cardiovascular risk, suggests a study published in the Diabetes, Obesity and Metabolism.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective therapies for the treatment of type 2 diabetes. In addition to improving glycaemic control and reducing body weight, they have shown efficacy in reducing major adverse cardiovascular events (MACE).1 While glucose-lowering and weight loss probably contribute to reduced cardiovascular risk, they do not account for the full effect,2 and additional mechanisms, including improvement in endothelial dysfunction and reduction of inflammation, may also contribute.
A group of researchers from U.S.A conducted a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with type 2 diabetes.
The results of the study are as follows:
· At 26 weeks, tirzepatide 10 and 15 mg decreased YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 levels versus baseline, and YKL-40 and leptin levels versus placebo and dulaglutide.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.